A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with binge eating disorder

About this resource

Previous studies support the use of selective serotonin reuptake inhibitors (SSRIs), in overweight patients with Binge Eating Disorder (BED), but results are far from conclusive. Sertraline has been studied less extensively, and there have been a few studies concerning SSRIs that report follow-up data at more than 12 weeks of follow-up. The present study assesses the effectiveness of sertraline and fluoxetine over a period of 24 weeks in obese patients with BED (DSM-IV-TR). Forty-two obese outpatients were randomized and assigned to one of two different drug treatments: 22 were treated with sertraline (dose range: 100-200 mg/day) and 20 with fluoxetine (dose range: 40-80 mg/day). Subjects were assessed at baseline and at 8, 12, and 24 weeks of treatment for binge frequency, weight loss, and severity of psychopathology. No significant differences were found between the two treatments. After 8 weeks of treatment a significant improvement in the Binge Eating Scale score and a significant weight loss emerged. These results were maintained by responders (weigh loss of at least 5 % of baseline weight) over 24 weeks. The results suggest that a 6-month treatment with SSRI may be an effective option to treat patients with BED.

AuthorLeombruni, Paolo; Piero, Andrea; Lavagnino, Luca; Brustolin, Annalisa; Campisi, Stefania & Fassino, Secondo
JournalProgress in Neuro-Psychopharmacology and Biologica

See also

Examining duration of binge eating episodes in binge eating disorder

OBJECTIVE: The primary goal of this article is to examine and clarify characteristics of binge eating in individuals with binge eating disorder (BED), particularly the duration of binge eating episodes, as well as potential differences between individuals with shorter compared to longer binge eating episodes.

Read more

Reduction of bulimia nervosa symptoms after psychostimulant initiation in patients with comorbid ADHD: Five case reports

Studies reveal a higher occurrence of bulimia nervosa (BN) in patients with attention deficit/hyperactivity disorder (ADHD) compared to controls.

Read more

Assessment of executive functioning in binge-eating disorder independent of weight status

Objective: Executive functioning (EF) problems may serve as vulnerability or maintenance factors for Binge-Eating Disorder (BED).

Read more

Pharmacotherapy of binge-eating disorder: A review

Objectives: The purpose of this article is to provide a comprehensive review of pharmacotherapy for binge eating disorder, including new therapeutic approaches such as centrally acting sympathomimetics, nootropics, lisdexamfetamine, and substance abuse treatment agents such as acamprosate, sodium oxybate, baclofen, and naltrexone.

Read more

Help us improve!

Give us feedback!

We will continue throughout 2020 to update and improve the NEDC website and welcome any feedback you may have on the site.

Provide feedback